David W Shields

US Patent:

7155896, Jan 2, 2007

Filed:

Jul 14, 2004

Appl. No.:

10/891266

Inventors:

Harvey B. Jansen - Mesa AZ, US
David K. Shields - Mesa AZ, US

Assignee:

Jansen's Aircraft Systems Controls, Inc. - Tempe AZ

International Classification:

F02G 3/00

US Classification:

60 39094, 60734, 251 636, 251 62

Abstract:

A system for draining fuel from the combustion chamber of a gas turbine engine in the event of a false start includes associated passageways and a straight through flow pilot air actuated poppet valve. The valve is normally open and actuated by the pilot air to close off the combustion chamber from the drain. A return spring biases the valve to open upon release of pilot air pressure acting on the valve. The valve housing has a piston section with a pilot air chamber and a section defining the passageways for the drain. The drain passageway extends along a straight path at an oblique angle to a piston axis along which a piston actuator moves in response to the return spring and/or the pilot air pressure. The valve also includes a position feedback system for detecting the state of the valve.

US Patent:

7524812, Apr 28, 2009

Filed:

Jul 31, 2007

Appl. No.:

11/831696

Inventors:

David J. Ellis - Los Altos CA, US
George P. Miljanich - Redwood City CA, US
David E. Shields - San Lorenzo CA, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA

International Classification:

A61K 38/00
C07K 14/00
C07K 7/00

US Classification:

514 2, 514 12, 530300, 530324, 424 91

Abstract:

The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.

US Patent:

7833973, Nov 16, 2010

Filed:

Jun 12, 2009

Appl. No.:

12/483673

Inventors:

David J. Ellis - Los Altos CA, US
George P. Miljanich - Redwood City CA, US
David E. Shields - San Lorenzo CA, US

Assignee:

Azur Pharma International Limited - Hamilton

International Classification:

A61K 38/00
C07K 7/00
C07K 14/00

US Classification:

514 2, 514 12, 530300, 530324, 424 91

Abstract:

The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.

US Patent:

7956030, Jun 7, 2011

Filed:

Oct 5, 2010

Appl. No.:

12/898525

Inventors:

David J. Ellis - Los Altos CA, US
George P. Miljanich - Redwood City CA, US
David E. Shields - San Lorenzo CA, US

Assignee:

Azur Pharma International Limited - Hamilton

International Classification:

A61K 38/00
C07K 14/00
C07K 7/00

US Classification:

514 2, 514 12, 530300, 530324, 424 91

Abstract:

The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.

US Patent:

7977307, Jul 12, 2011

Filed:

Oct 5, 2010

Appl. No.:

12/898516

Inventors:

David J. Ellis - Los Altos CA, US
George P. Miljanich - Redwood City CA, US
David E. Shields - San Lorenzo CA, US

Assignee:

Azur Pharma International Limited - Hamilton

International Classification:

A61K 38/00
C07K 14/00
C07K 7/00

US Classification:

514 2, 514 12, 530300, 530324, 424 91

Abstract:

The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.

US Patent:

8066474, Nov 29, 2011

Filed:

Jun 15, 2007

Appl. No.:

11/764149

Inventors:

Harvey B. Jansen - Mesa AZ, US
David K. Shields - Mesa AZ, US

Assignee:

Jansen's Aircraft Systems Controls, Inc. - Tempe AZ

International Classification:

F01B 25/02

US Classification:

415160, 91363 R, 2511291

Abstract:

A variable guide vane actuator for positioning the guide vanes of a turbine engine in a hypersonic missile uses compressor exhaust to drive a linked, floating piston assembly that is coupled to the guide vanes. The relatively low pressure compressor exhaust is metered by a valve to drive the piston arrangement to accurately position the guide vanes in proportion to the input control signal. Reliability and accuracy gains are achieved by inhibiting the effects of vibration and thermal distortion through the elimination of piston/bore contact, the use of a rigid, cantilevered mounting arrangement and cooling with the pre-combusted liquid fuel.

US Patent:

8226359, Jul 24, 2012

Filed:

Nov 28, 2011

Appl. No.:

13/305483

Inventors:

Harvey B. Jansen - Mesa AZ, US
David K. Shields - Mesa AZ, US

Assignee:

Jansen's Aircraft Systems Controls, Inc. - Tempe AZ

International Classification:

F01D 17/16

US Classification:

415160, 91363 R, 92144

Abstract:

A variable guide vane actuator for positioning the guide vanes of a turbine engine in a hypersonic missile uses compressor exhaust to drive a linked, floating piston assembly that is coupled to the guide vanes. The relatively low pressure compressor exhaust is metered by a valve to drive the piston arrangement to accurately position the guide vanes in proportion to the input control signal. Reliability and accuracy gains are achieved by inhibiting the effects of vibration and thermal distortion through the elimination of piston/bore contact, the use of a rigid, cantilevered mounting arrangement and cooling with the pre-combusted liquid fuel.

US Patent:

8268774, Sep 18, 2012

Filed:

Jul 5, 2011

Appl. No.:

13/176568

Inventors:

David J. Ellis - Los Altos CA, US
George P. Miljanich - Redwood City CA, US
David E. Shields - San Lorenzo CA, US

Assignee:

Azur Pharma International Limited - Hamilton

International Classification:

A61K 38/00
C07K 14/00
C07K 7/00

US Classification:

514 2, 514 12, 530300, 530324, 424 91

Abstract:

The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.